SAFETY AND EFFICACY OF BENDAMUSTINE WITH OR WITHOUT RITUXIMAB IN THE TREATMENT OF HEAVILY PRETREATED PATIENTS WITH LYMPHOMA OR CLL. A MULTICENTER RETROSPECTIVE STUDY

被引：0
|
作者：
Rigacci, L. [1 ]
Puccini, B. [1 ]
D'Arco, A. [2 ]
Orciuolo, E. [3 ]
Cortelazzo, S. [4 ]
Gaidano, G. [5 ]
Patti, C. [6 ]
Musto, P. [7 ]
Zinzani, P. L. [8 ]
Storti, S. [9 ]
Carpaneto, A. [10 ]
Di Renzo, N. [11 ]
Cascavilla, N. [12 ]
Petrizzi, V. Belsito [2 ]
Cecconi, N. [3 ]
Buda, G. [3 ]
Franceschetti, S. [5 ]
Derenzini, E.
Costa, A. [6 ]
Giordano, G. [9 ]
Montanaro, M. [10 ]
Billio, A. [4 ]
Mansueto, G. [7 ]
Bosi, A. [1 ]
机构：
[1] Azienda Osped Careggi, Florence, Italy
[2] Ematooncol Nocera Inferiore, Nocera Inferiore, Italy
[3] Dept Oncol Transplans & Adv, Pisa, Italy
[4] Ematol Osped Reg Bolzano, Bolzano, Italy
[5] Dpt Clin & Expt Med, Div Hematol, Novara, Italy
[6] Ematol Osped Cervello, Palermo, Italy
[7] Ctr Riferimento Oncol Basilicata, IRCCS, Rionero In Vulture, Italy
[8] Ematol Osped L&A Seragnoli, Bologna, Italy
[9] Univ Cattolica Sacro Cuore, UOC Oncoematol, Campobasso, Italy
[10] Ematol Osped Roncigl, Viterbo, Italy
[11] Ematol Osped V Fazzi, Lecce, Italy
[12] Ematol Casa Sollievo Sofferenza, San Giovanni Rotondo, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0431
引用
收藏
页码：175 / 175
页数：1
相关论文
共 50 条
  • [41] Safety and Efficacy of Intrathecal Rituximab in Children with Non-Hodgkin Lymphoma: A Retrospective Study
    Xiong, X.
    Li, Y.
    Peng, X.
    Chuchu, F.
    Pingping, W.
    Wenjun, W.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S590 - S590
  • [42] A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma
    Nobuhiko Nakamura
    Senji Kasahara
    Junichi Kitagawa
    Hiroshi Nakamura
    Michio Sawada
    Kenji Fukuno
    Yuhei Shibata
    Yuto Kaneda
    Takeshi Hara
    Nobuhiro Kanemura
    Hisashi Tsurumi
    Masahito Shimizu
    Experimental Hematology & Oncology, 11
  • [43] Lenalidomide and Rituximab for the Initial Treatment of Patients with Chronic Lymphocytic Leukemia (CLL) A Multicenter Study of the CLL Research Consortium
    James, Danelle F.
    Brown, Jennifer R.
    Werner, Lillian
    Wierda, William G.
    Barrientos, Jaqueline C.
    Castro, Januario
    Greaves, Andrew
    Rassenti, Laura Z.
    Rai, Kanti R.
    Neuberg, Donna
    Kipps, Thomas J.
    BLOOD, 2011, 118 (21) : 135 - 135
  • [44] A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma
    Nakamura, Nobuhiko
    Kasahara, Senji
    Kitagawa, Junichi
    Nakamura, Hiroshi
    Sawada, Michio
    Fukuno, Kenji
    Shibata, Yuhei
    Kaneda, Yuto
    Hara, Takeshi
    Kanemura, Nobuhiro
    Tsurumi, Hisashi
    Shimizu, Masahito
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2022, 11 (01)
  • [45] Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study
    Mondello, Patrizia
    Steiner, Normann
    Willenbacher, Wolfgang
    Cerchione, Claudio
    Nappi, Davide
    Mauro, Endri
    Ferrero, Simone
    Cuzzocrea, Salvatore
    Mian, Michael
    ONCOLOGIST, 2018, 23 (04): : 454 - 460
  • [46] Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings
    Czuczman, Myron S.
    Goy, A.
    Lamonica, D.
    Graf, D. A.
    Munteanu, M. C.
    van der Jagt, R. H.
    ANNALS OF HEMATOLOGY, 2015, 94 (12) : 2025 - 2032
  • [47] Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings
    Myron S. Czuczman
    A. Goy
    D. Lamonica
    D. A. Graf
    M. C. Munteanu
    R. H. van der Jagt
    Annals of Hematology, 2015, 94 : 2025 - 2032
  • [48] BENDAMUSTINE (B) IN COMBINATION WITH RITUXIMAB (R) FOR PATIENTS WITH RELAPSED/RESISTANT CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): AN ITALIAN MULTICENTRE RETROSPECTIVE STUDY
    Iannitto, E.
    Morabito, F.
    Mancuso, S.
    Gentile, M.
    Augello, A.
    Bongarzoni, V.
    Cascavilla, N.
    D'Arco, A.
    Di Renzo, N.
    Fazzi, R.
    Ferrara, F.
    Franco, G.
    Gobbi, M.
    Liardo, E.
    Liberati, A. M.
    Marasca, R.
    Montanini, A.
    Mule, A.
    Musso, M.
    Musto, P.
    Pennese, E.
    Piccin, A.
    Scalabrini, D. Rota
    Sciacca, M.
    Visani, G.
    Abbadessa, V.
    Rigacci, L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 323 - 323
  • [49] Efficacy and Safety of Bendamustine-Rituximab as Frontline Therapy for Indolent Non-Hodgkin Lymphoma: A Real-World, Single-Center, Retrospective Study
    Chan, Tevy
    Champagne, Jean-Nicolas
    Boudreault, Jean-Samuel
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (08)
  • [50] COMPARISON OF FIRST-LINE TREATMENT WITH BENDAMUSTINE PLUS RITUXIMAB VERSUS R-CHOP FOR PATIENTS WITH FOLLICULAR LYMPHOMA GRADE 3A: RESULTS OF AN ITALIAN MULTICENTER, RETROSPECTIVE STUDY
    Margiotta-Casaluci, G.
    Bigliardi, S.
    Cocito, F.
    Meli, E.
    Petrucci, L.
    Nicolosi, M.
    Annibali, O.
    Boccomini, C.
    Bozzola, V.
    Castellino, A.
    Cattina, F.
    Cenfra, N.
    Ciavarella, S.
    Kovalchuk, S.
    Rotondo, F.
    Fama, A.
    Olivieri, J.
    Zaja, F.
    HAEMATOLOGICA, 2021, 106 (10) : 91 - 91
12345